Skip to main content

Table 2 Trajectory of costs under Medicare Part D for breast cancer adjuvant endocrine agents before and after availability of generic alternatives

From: Erratum to: Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations

Medication Monthly cost after deductible Monthly cost in gap Monthly cost in catastrophic
Median of state mean costs Median of state mean costs Median of state mean costs
$, (Range of mean costs) $, (Range of mean costs) $, (Range of mean costs)
2007 2011a Change (%) 2007 2011a Change (%) 2007 2011a Change (%)
Arimidex/Anastrozole 39.64 (38.37–48.19) 9.57 (8.00–11.95) −76 258.64 (247.44–263.47) 38.94 (31.80–78.46) −85 13.18 (12.68–13.32) 3.72 (3.39–6.19) −72
Aromasin/Exemestane 42.57 (40.72–50.94) 49.50 (42.34–118.68) +16 267.56 (255.21–273.62) 244.51 (228.61–270.95) −9 13.66 (13.07–13.79) 14.41 (13.51–71.41) +6
Femara/Letrozole 41.92 (39.38–51.11) 69.31 (59.69–85.17) +65 277.65 (249.14–282.54) 225.13 (209.10–252.23) −19 14.16 (12.96–14.34) 38.53 (33.70–57.15) +172
Tamoxifen 6.19 (5.95–9.22) 5.54 (5.12–6.89) −11 21.32 (20.36–25.42) 13.17 (12.44–21.11) −38 2.26 (2.20–2.70) 2.73 (2.50–3.47) +21
  1. aFirst year generic formulation was available to Medicare Part D beneficiaries; generic cost provided